The authors have declared that no competing interests exist.
Oral nutritional supplements (ONS) have been shown to improve patient outcomes in the hospital setting, but limited results from long-term care or community settings exist. Using electronic health records (EHRs) from 2009 to 2014 for both adult inpatients and outpatients, we compare the demographic and clinical characteristics of patients who received ONS (n = 1,251) with a non-ONS control group (n =25,513). Multivariable logistic regression modeling was used to describe and compare differences in baseline characteristics between the groups including age, sex, race, tobacco use, and comorbidities. We found that patients receiving ONS were older and sicker than control patients. Hospitalized ONS patients were more likely to be admitted from the emergency department and have a hospitalization within the last month prior to the index date. Our results suggest that there is a need for nutrition screening and incorporating nutrition status into the EHR as an important way to coordinate hospital and community medical care. ONS can be an important therapy for vulnerable populations in both the hospital and the community settings.
Malnutrition is a serious and undertreated problem in both the hospital and community settings. Malnourished patients face greater risk of poor functional, clinical, and economic outcomes. For example, poor nutritional status is associated with a heightened risk of comorbid complications
Malnutrition is prevalent in 30-50% of patients at the time of hospital admission
A growing body of evidence has shown oral nutritional supplements (ONS), which consist of both macronutrients and micronutrients, to be a cost-effective way to prevent and treat malnutrition and to improve patient outcomes
This study aims to better understand the delivery of ONS as an important therapy in both inpatient and outpatient settings, with patients in the outpatient setting experiencing a hospitalization within the last year. Specifically, we compared the characteristics of patients receiving ONS to those of patients who were not. This research contributes to the literature by demonstrating the patterns of ONS usage in a large integrated health system throughout the continuum of care over a 6 year time period.
This analysis was conducted using an electronic health records (EHR) database from Geisinger Health System, which primarily serves residents throughout 45 counties in central and northeast Pennsylvania. The EHR database contains clinical data from outpatient and inpatient encounters across approximately 100 facilities for more than 4 million distinct patients since 1996. The study sample was restricted to adults 18 years or older with healthcare system encounters (e.g., outpatient visit, hospitalization or emergency department visit) from January 2008 through May 2015. Because all data was received from a health system data broker in deidentified form, the Geisinger Institutional Review Board waived the requirement for review.
Patients were initially identified with a prescription order for any product in the nutritional supplements category between 2009 and 2014 (2008 and 2015 were excluded to account for a run in and wash out period), based on the system’s medication order classification system. We excluded prescriptions that were ordered to be administered “continuously” or in units of “mL/hour” which implied a tube feeding method of delivery as opposed to oral consumption. The date of the first order was defined as the patient’s index date.
The majority of ONS patients had multiple comorbidities and either received their first ONS prescription order in an inpatient setting or had been recently admitted to an inpatient facility. To minimize heterogeneity and ensure an adequate medical history for patients in our sample, our final study cohort focused on ONS patients with a recent history of inpatient utilization. Therefore, inclusion criteria were: (1) patients were age 18 years or older on the index date; (2) patients had at least one hospitalization within 12 months prior to the index date; (3) patients had at least 6 months history of encounters prior to the index date; (4) patients had at least 12 months history of encounters after the index date; (5) patients had scored 2 or higher on the Charlson Comorbidity Index, and; (6) patients had more than two ONS prescription orders. These criteria yielded an initial population of 1,251 ONS patients.
We also identified 168,110 potential control patients (non-ONS users) for comparison purposes. Since there was no ONS order defining an index date, an encounter date for each control was randomly selected to be the index date. To ensure similar follow-up between ONS and controls, control patients were also required to meet the same criteria as the treatment group, with the exception of ONS orders.
Baseline characteristics of all ONS and control patients were calculated as of their index date. Additionally, we found that there were no patients in the ONS group with a primary index encounter diagnosis of stable angina, unstable angina, or type 1 diabetes, and so any patients in the control group with these primary diagnoses were excluded, leaving a final control population of 25,513 patients.
Baseline demographics, comorbidities, and hospitalization characteristics were reported descriptively using means with standard deviations or medians with interquartile ranges (as applicable) for continuous variables, and raw counts with percentages for categorical measures. Associations expressed as adjusted odds ratios (OR) with 95% confidence intervals (CI) were computed using multivariable logistic regression. Specifically, we estimated each patient’s probability of being an ONS user as a function of sex, age, race (Caucasian or other), smoking status, prior diagnoses, Charlson Comorbidity Index (CCI), primary diagnosis at the index encounter, index encounter type (inpatient or other, and whether the patient was admitted via emergency department), length of time since most recent hospitalization, and payor type. The CCI does not contain any eating disorder or gastrointestinal causes of malnutrition except for peptic ulcer. We find no patients in the ONS cohort with dysphagia, anorexia, or unspecified eating disorders. In the control cohort, there were 1,824 patients with a diagnosis of dysphagia (7%), 294 patients with a diagnosis of anorexia (1%), and no patients with the diagnosis for unspecified eating disorders. There are two implications for our results
The diagnosis of malnutrition are the following ICD-9 codes: 260 (Kwaslorkor), 261 (Nutriional Marasmus), 262 (other severe, protein-calorie malnutrition, 263 (Other unspecified protein-energy malnutrition), 263.0 (moderate malnutrition), 263.1 (mild malnutrition), 263.2 (arrested development following protein-calorie malnutrition), 263.8 (other protein-calorie malnutrition), 263.9 (unspecified protein-calorie malnutrition), 285.9 (anemia nos), 783.22 (underweight) and 783.21 (abnormal loss of weight).
Reported
|
|
|
|
|
No. of patients | 1,251 | 25,513 | ||
Males | 580 (46%) | 12,094 (47%) | 0.94 (0.80, 1.10) | 0.42 |
Age at index date | ||||
18-39 | 50 (4%) | 1842 (7%) | ref. | ref. |
40-49 | 75 (6%) | 2738 (11%) | 0.87 (0.55, 1.38) | 0.55 |
50-59 | 136 (11%) | 4930 (19%) | 0.89 (0.58, 1.35) | 0.57 |
60-69 | 225 (18%) | 6392 (25%) | 1.17 (0.77, 1.78) | 0.47 |
70-79 | 288 (23%) | 6535 (26%) | 2.24 (1.46, 3.45) | 0.0002 |
80-89 | 371 (30%) | 2859 (11%) | 5.23 (3.37, 8.14) | <0.0001 |
90+ | 106 (8%) | 217 (1%) | 19.76 (11.47, 34.05) | <0.0001 |
Mean (SD) | 72 (15) | 63 (15) | ||
Median IQR | 75 62 84 | 65 53 74 | ||
White/Caucasian | 1222 (98%) | 25,099 (98%) | 0.65 (0.37, 1.12) | 0.12 |
Smoking | ||||
Never | 523 (42%) | 10863 (42%) | ref. | ref. |
Current Smoker | 172 (14%) | 3457 (14%) | 1.03 (0.87. 1.23) | 0.72 |
Quit | 530 (42%) | 10601 (42%) | 1.04 (0.92, 1.18) | 0.55 |
Unknown/Not Asked | 26 (2%) | 592 (2%) | 0.91 (0.61, 1.36) | 0.65 |
ref. indicates reference value for variables with >2 categories.
SD standard deviation.
IQR inter-quartile range.
Baseline Mean (SD) | Year 1 Mean (SD) | Year 2 Mean (SD) | Year 3 Mean (SD) | Year 4 Mean (SD) | |
Control | 30.5 (7.3) (n=25,181) | -0.04 (2.0) (n=24,639) | -0.06 (2.4) (n=23,346) | -0.10 (2.5) (n=21,750) | -0.14 (2.6) (n=20,048) |
ONS | 25.4 (7.1) (n=1,159) | 0.05 (3.1) (n=678) | 0.4 (3.8) (n=406) | 0.7 (3.9) (n=224) | 1.3 (3.9) (n=112) |
At the baseline index date, the average ONS patient had lower BMI than control group. However, the ONS cohort’s BMIs have steadily increased over the time after receiving ONS while the Control group’s BMIs slightly decreased over time. Thus, patients receiving ONS showed steadily increasing weight gain over the treatment period, on average, whereas the control cohort showed steadily decreasing BMI’s over the time.
|
|
|
|
|
No. of patients Comorbidities at index date | 1,251 | 25,513 | -- | |
AIDS | 6 (<1%) | 54 (<1%) | 0.85 (0.17, 4.21) | 0.84 |
AMI, any prior | 199 (16%) | 2321 (9%) | 1.60 (1.10, 2.33) | 0.01 |
AMI, recent (last 12 months) | 116 (9%) | 1514 (6%) | 1.08 (0.70, 1.66) | 0.72 |
Chronic obstructive pulmonary disease | 687 (55%) | 11074 (43%) | 1.30 (1.07, 1.57) | 0.008 |
Congestive heart failure | 528 (42%) | 5503 (22%) | 1.01 (0.80, 1.27) | 0.93 |
Coronary artery bypass graft procedure | 25 (2%) | 444 (2%) | 1.74 (0.88, 3.41) | 0.11 |
Coronary heart disease | 581 (46%) | 9258 (36%) | 0.92 (0.76, 1.13) | 0.43 |
Coronary revascularization procedure | 65 (5%) | 1670 (7%) | 0.77 (0.49, 1.19) | 0.24 |
Dementia | 118 (9%) | 580 (2%) | 2.04 (1.49, 2.79) | <0.0001 |
Hemiplegia | 103 (8%) | 717 (3%) | 1.61 (1.10, 2.34) | 0.01 |
Hyperlipidemia | 857 (69%) | 18800 (74%) | 0.86 (0.71, 1.04) | 0.11 |
Hypertension | 1020 (82%) | 19636 (77%) | 1.02 (0.81, 1.29) | 0.86 |
Ischemic stroke | 207 (17%) | 1823 (7%) | 1.40 (1.09, 1.81) | 0.009 |
Leukemia | 22 (2%) | 321 (1%) | 0.70 (0.37, 1.32) | 0.27 |
Lymphoma | 126 (10%) | 2561 (10%) | 0.83 (0.61, 1.14) | 0.25 |
Malignancy, any | 496 (40%) | 7906 (31%) | 1.02 (0.79, 1.32) | 0.87 |
Metastasis, any | 162 (13%) | 1364 (5%) | 0.83 (0.45, 1.53) | 0.55 |
Mild liver disease | 266 (21%) | 3120 (12%) | 1.85 (1.47, 2.33) | <0.0001 |
Moderate to severe liver disease | 58 (5%) | 325 (1%) | 1.34 (0.78, 2.30) | 0.3 |
Peptic ulcer disease | 125 (10%) | 1016 (4%) | 1.36 (0.99, 1.85) | 0.05 |
Peripheral vascular disease | 576 (46%) | 7227 (28%) | 1.20 (0.95, 1.51) | 0.12 |
Renal disease | 569 (45%) | 6438 (25%) | 1.15 (0.64, 2.08) | 0.64 |
Rheumatic disease | 118 (9%) | 1807 (7%) | 0.93 (0.69, 1.25) | 0.64 |
Stable angina | 148 (12%) | 2140 (9%) | 1.55 (1.19, 2.03) | 0.001 |
Type 1 diabetes | 119 (10%) | 1622 (7%) | 1.38 (1.04, 1.83) | 0.03 |
Type 2 diabetes | 559 (45%) | 10434 (41%) | 2.65 (1.25, 5.64) | 0.01 |
Unstable angina, any prior | 107 (9%) | 1815 (7%) | 0.85 (0.57, 1.26) | 0.41 |
Unstable angina, recent (last 12 months) | 38 (3%) | 973 (4%) | 0.71 (0.40, 1.26) | 0.24 |
Charlson Comorbidity Index (CCI) | ||||
Mean (SD) | 6.9 (3.8) | 4.7 (2.9) | 1.23 (1.12, 1.34) |
<0.0001 |
Median (IQR) | 6 (4, 9) | 4 (2, 6) |
SD standard deviation.
IQR inter-quartile range.
Odds ratio corresponding to 1-unit increase in CCI.
ONS Patients N (%) | Control Patients N (%) | Adjusted Odds Ratio (95% CI) | P-value | |
No. of patients | 1,251 | 25,513 | -- | -- |
Encounter type | ||||
Outpatient / ED Only | 860 (69%) | 20246 (80%) | ref. | ref. |
Inpatient only | 132 (11%) | 2722 (11%) | 1.75 (1.55, 1.98) |
<0.0001 |
Inpatient + ED | 259 (21%) | 2545 (10%) | 2.35 (1.74, 3.18) |
<0.0001 |
Charlson Comorbidity Index: Primary diagnosis at index encounter | ||||
AIDS | 2 (<1%) | 9 (<1%) | 2.99 (0.11, 80.28) | 0.51 |
AMI | 11 (<1%) | 187 (<1%) | 0.52 (0.14, 1.99) | 0.34 |
Chronic obstructive pulmonary disease | 36 (3%) | 978 (4%) | 0.94 (0.61, 1.45) | 0.76 |
Congestive heart failure | 53 (4%) | 824 (3%) | 0.62 (0.42, 0.91) | 0.01 |
Coronary heart disease | 19 (2%) | 1004 (4%) | 0.43 (0.24, 0.75) | 0.003 |
Dementia | 4 (<1%) | 25 (<1%) | 0.22 (0.05, 1.05) | 0.06 |
Hemiplegia | 3 (<1%) | 22 (<1%) | 2.04 (0.41, 10.12) | 0.38 |
Hyperlipidemia | 4 (<1%) | 377 (1%) | 0.59 (0.20, 1.77) | 0.35 |
Hypertension | 38 (3%) | 1224 (5%) | 0.65 (0.43, 1.00) | 0.049 |
Ischemic stroke | 8 (<1%) | 195 (<1%) | 0.58 (0.20, 1.72) | 0.33 |
Leukemia | 1 (<1%) | 69 (<1%) | 0.15 (0.01, 1.64) | 0.12 |
Lymphoma | 2 (<1%) | 49 (<1%) | 1.02 (0.20, 5.23) | 0.98 |
Malignancy, any | 147 (12%) | 2425 (10%) | 1.45 (1.10, 1.92) | 0.009 |
Metastasis, any | 14 (1%) | 193 (1%) | 0.50 (0.23, 1.08) | 0.08 |
Mild liver disease | 20 (2%) | 165 (1%) | 1.52 (0.75, 3.09) | 0.25 |
Moderate to severe liver disease | 3 (<1%) | 40 (<1%) | 0.22 (0.04, 1.15) | 0.07 |
Peptic ulcer disease | 5 (<1%) | 55 (<1%) | 1.14 (0.29, 4.54) | 0.85 |
Peripheral vascular disease | 38 (3%) | 444 (2%) | 2.25 (1.27, 3.99) | 0.006 |
Renal disease | 92 (7%) | 563 (2%) | 2.31 (1.64, 3.24) | <0.0001 |
Rheumatic disease | 9 (<1%) | 187 (1%) | 2.29 (0.95, 5.54) | 0.07 |
Type 2 diabetes | 54 (4%) | 2282 (9%) | 1.61 (0.25, 10.49) | 0.62 |
Primary insurer type | ||||
Commercial | 462 (37%) | 20,921 (82%) | ref. | ref. |
Medicare | 449 (36%) | 907 (4%) | 22.4 (19.4, 25.9) | <0.0001 |
Medicaid | 58 (5%) | 216 (1%) | 12.2 (9.0, 16.5) | <0.0001 |
All Other | 282 (23%) | 3469 (14%) | 3.7 (3.2, 4.3) | <0.0001 |
Time since last hospitalization | ||||
<2 weeks | 538 (43%) | 4848 (19%) | 2.35 (1.90, 2.89) | <0.0001 |
2 weeks to <1 month | 208 (17%) | 3220 (13%) | 1.54 (1.21, 1.97) | 0.0005 |
1 to <3 months | 259 (21%) | 5943 (23%) | ref. | ref. |
3 to <6 months | 136 (11%) | 4869 (19%) | 0.67 (0.51, 0.88) | 0.003 |
6 to 12 months | 110 (9%) | 6633 (26%) | 0.49 (0.37, 0.64) | <0.0001 |
ref. indicates reference value for variables with >2 categories.
Odds Ratio corresponding to inpatient vs. all other encounters.
Odds Ratio corresponding to inpatient admitted via ED vs. all others.
Even after controlling for age, gender, race, current comorbidities and primary diagnosis on the index date, patients with higher CCI were more likely to be prescribed ONS (OR=1.23; CI=1.12-1.34;
In the inpatient setting, the five most common physician specialties that ordered ONS were internal medicine (36%), critical care medicine (16%), general surgery (14%), cardiovascular medicine (4%) and thoractic/cardiac surgery (4%). In comparison, in outpatient encounters, the five most common provider specialties were family practice (19%), internal medicine (13%), physician assistant (12%), nurse practitioner (9%) and general surgery (5%).
This study represents a detailed description of ONS use in both inpatient and outpatient settings in a large integrated health system in the United States. The most common populations and diagnoses for which ONS was used over a 6-year period are described. Overall, our data showed that ONS patients were older, sicker (CCI of 6.9 vs. 4.7, p < 0.0001) and much more likely to be admitted from emergency departments (21% vs. 10%, p<0.0001) than non-ONS control patients.
Beyond diagnoses included in the CCI, the most frequent of
This study has several limitations. The data represent hospitals located in a mostly rural region of Pennsylvania where patients are predominantly white; therefore, results of the study may not be generalizable to more diverse or urban population. Since ONS does not require a prescription, many of the orders were documented during medical reconciliation which could result in misclassification of non-ONS patients who actually were consuming the product without a documented order. However, this is a common limitation associated with any studies employing retrospective designs. Finally, data on the compliance, dosage, and duration of use of ONS were not available. Future studies employing prospective study designs with more diverse patient populations are needed.
This paper provides a description of ONS prescribing practices in both the inpatient and outpatient settings of an integrated health system. These data indicate that patients receiving ONS are older, have more comorbidities and are more likely to have been recently hospitalized. Given the negative health and financial impact of malnutrition, and the vulnerability of this population, these results highlight the importance of carefully screening patients for malnutrition. Although most hospitals implement some type of nutrition screening, practice varies widely between hospitals and patients are not always treated in a timely manner. In 2015, ASPEN called for a National Goal to address disease-related malnutrition in hospitalized patients. This call noted that “the standards and systems of care need to drive the process such that a patient identified to be “at nutrition risk” or who is in fact malnourished receives an intervention as rapidly as possible. In addition, nutrition must be addressed early in discharge planning so that it is identified in the transition from hospital to home or alternate care settings”
Although tools for screening malnutrition in outpatients exist
This study was funded by Abbott Nutrition. This study was a joint effort between Geisinger Health System and Abbott Nutrition, and Abbott Nutrition authors contributed to all aspects of the study.
The study was conducted at Geisinger Health System with unrestricted grant funding from Abbott Nutrition. All authors’ contributions to writing of the manuscript were at the request of and within the scope of their employment with Abbott Nutrition (for L.F., S.G., and J.P.) and Geisinger Health System (J. G., E.S.M. and L.H.). The information presented in the article is based on clinical evidence and is not affected by any financial relationship.
J.P. and S.G. formulate the research question. J.G., L.H. and E.S.M. designed the study and led the data analysis. L.F. led the manuscript writing. All authors contribute to the data interpretation and revisions of the manuscript. Ethics of Human Subject Participation: Ethical approval was not required.
We’d like to thank Dr. Suela Sulo for helpful comments on the manuscript.